Protein phosphorylation plays an important role in physiological processes, such as muscle contraction. Phospho-specific antibodies have become powerful tools to study these processes. Cardiac myosin binding protein-C...Protein phosphorylation plays an important role in physiological processes, such as muscle contraction. Phospho-specific antibodies have become powerful tools to study these processes. Cardiac myosin binding protein-C (cMyBP-C) is one of the proteins that make up the contractile apparatus of cardiomyocytes. Phosphorylation of cMyBP-C is essential for normal cardiac function, since dephosphorylation of this protein leads to its degradation and has been associated with cardiomyopathy. One of the upstream kinases, which phosphorylate cMyBP-C, is protein kinase D (PKD). While studying the role of PKD in cMyBP-C phosphorylation, we tried to analyze phosphorylation of PKD with a phospho-specific PKD-Ser744/748 antibody. Contrary to the expected 115 kDa, a signal was found for a 150-kDa protein. By MALDI-TOF mass spectrometry, we identified this protein to be cMyBP-C. These data were confirmed by immunostaining using the p-PKD-Ser744/748 antibody, which displayed a striated pattern similar to the one observed for a regular cMyBP-C antibody. To our knowledge there are no antibodies commercially available for phosphorylated cMyBP-C. Thus, the p-PKD-Ser744/748 antibody can accelerate research into the role of cMyBP-C phosphorylation in cardiomyocytes.展开更多
Since its discovery, myosin-binding protein C (cMyBP-C) has become a protein of interest clinically. With emergence of new methodologies and technologies, the structure and functions of cMyBP-C from different aspects ...Since its discovery, myosin-binding protein C (cMyBP-C) has become a protein of interest clinically. With emergence of new methodologies and technologies, the structure and functions of cMyBP-C from different aspects can be studied, enabling us to better understand its involvement in certain cardiac conditions. Studying its kinetics of release and clearance from the circulation and by comparing to other conventional biomarkers, it has been reported that cMyBP-C is eligible to be a novel biomarker for several cardiac conditions. Moreover, studying the genetics and their involvement in pathogenic mechanisms has opened the ideas for potential therapeutic strategies. More and more researches are constantly being done to better understand the role of cMyBP-C in dilated cardiomyopathy (DCM). The importance of cMyBP-C to the heart is still actively being investigated. Its presence is however crucial for sarcomere organization and proper regulation of cardiac contraction during systole and complete relaxation during diastole. Genetic mutation in cMyBP-C has been linked to cardiac conditions including hypertrophic and dilated cardiomyopathies. Around 350 types of mutations have already been documented leading to various cardiac conditions and abnormalities. Analyzing human heart samples has enabled us to better understand the importance of cMyBP-C and how its mutations lead to inherited cardiomyopathies. It is therefore necessary to have an update about the research progress of cMyBP-C in relation to DCM and other cardiac conditions.展开更多
目的探讨血清心脏肌球蛋白结合蛋白C(c My BP-C)在急性心肌梗死(AMI)患者诊断中的价值。方法选择2014年3月至2015年11月心血管内科收治的AMI患者62例作为病例组,选取正常体检者60例作为对照组。采用双抗体夹心酶联免疫吸附试验(ELISA)...目的探讨血清心脏肌球蛋白结合蛋白C(c My BP-C)在急性心肌梗死(AMI)患者诊断中的价值。方法选择2014年3月至2015年11月心血管内科收治的AMI患者62例作为病例组,选取正常体检者60例作为对照组。采用双抗体夹心酶联免疫吸附试验(ELISA)法检测血清c My BP-C浓度。比较AMI组与对照组间c My BP-C、肌钙蛋白Ⅰ(c TnⅠ)、肌酸激酶同工酶(CK-MB)和肌红蛋白(Myo)浓度的差异,分析AMI组c My BP-C与c TnⅠ、CKMB和Myo的相关性,同时分析发病时间小于4 h的AMI患者入院时血清c My BP-C和c TnⅠ浓度与对照组的差异,比较急诊经皮冠状动脉介入(PCI)术后12 h与入院时血清c My BP-C和c TnⅠ的差异。结果 AMI组患者血清c My BP-C、c TnⅠ、CK-MB和Myo浓度较对照组均明显升高(P<0.05)。相关性分析显示,AMI组患者c My BP-C浓度与c TnⅠ、CK-MB和Myo浓度均存在正相关(分别为r=0.876、P<0.05;r=0.632、P<0.05和r=0.903、P<0.05)。发病时间小于4 h的AMI患者入院时血清c My BP-C浓度较对照组明显升高(P<0.05),而血清c TnⅠ浓度与对照组比较差异无统计学意义(P>0.05)。行急诊PCI术后12 h血清c My BP-C浓度较入院时明显下降,而c TnⅠ浓度较入院时明显升高(P<0.05)。结论 AMI患者入院时血清c My BP-C、c TnⅠ、CK-MB和Myo浓度较对照组均显著升高且c My BP-C浓度与c TnⅠ、CK-MB和Myo浓度均存在正相关;c My BP-C在发病4 h内即开始升高,提示c My BP-C可以作为诊断AMI的早期生化标志物。AMI患者行急诊PCI术后12 h血清c My BP-C浓度较入院时明显下降,表明c My BP-C可以作为评估PCI术效果的早期指标。展开更多
目的探讨心肌肌球蛋白结合蛋白C(c My BP-C)在急性心肌梗死(AMI)中的表达及其临床意义。方法选取2011年1月至2013年12月临朐县人民医院收治的50例AMI患者作为AMI组,其中发病时间<4 h 21例,发病时间≥4 h 29例。另外选择同期健康体检...目的探讨心肌肌球蛋白结合蛋白C(c My BP-C)在急性心肌梗死(AMI)中的表达及其临床意义。方法选取2011年1月至2013年12月临朐县人民医院收治的50例AMI患者作为AMI组,其中发病时间<4 h 21例,发病时间≥4 h 29例。另外选择同期健康体检者50例作为健康对照组。统计受试者血清c My BP-C、心脏肌钙蛋白I(c Tn I)、肌红蛋白(Myo)水平,并分析AMI患者血清c My BP-C、c Tn I、Myo与年龄、发病时间、体质指数的相关性。结果 AMI组血清c My BP-C、c Tn I、Myo水平均高于健康对照组[(106±16)μg/L比(18±6)μg/L、(10.76±3.32)μg/L比(0.031±0.003)μg/L、(122±33)μg/L比(23±5)μg/L],差异有统计学意义(P<0.01)。发病时间≥4 h组患者血c My BP-C、Myo、c Tn I水平高于发病时间<4 h组[(109±17)μg/L比(76±9)μg/L,(11.67±3.72)μg/L比(0.042±0.006)μg/L,(130±33)μg/L比(93±16)μg/L,P<0.01]。PCI术后患者血c My BP-C水平低于入院时[(59±11)μg/L比(107±16)μg/L,P<0.01],PCI术后患者血c Tn I、Myo水平高于入院时[(33±6)μg/L比(11±3)μg/L,(136±35)μg/L比(122±33)μg/L,P<0.01];血c My BP-C、c Tn I、Myo与AMI发病时间均呈正相关(P<0.05);血c My BP-C、c Tn I、Myo之间均呈正相关(P<0.05)。结论 c My BP-C可以作为AMI早期诊断的指标之一,还可作为评价PCI术早期效果的指标。展开更多
文摘Protein phosphorylation plays an important role in physiological processes, such as muscle contraction. Phospho-specific antibodies have become powerful tools to study these processes. Cardiac myosin binding protein-C (cMyBP-C) is one of the proteins that make up the contractile apparatus of cardiomyocytes. Phosphorylation of cMyBP-C is essential for normal cardiac function, since dephosphorylation of this protein leads to its degradation and has been associated with cardiomyopathy. One of the upstream kinases, which phosphorylate cMyBP-C, is protein kinase D (PKD). While studying the role of PKD in cMyBP-C phosphorylation, we tried to analyze phosphorylation of PKD with a phospho-specific PKD-Ser744/748 antibody. Contrary to the expected 115 kDa, a signal was found for a 150-kDa protein. By MALDI-TOF mass spectrometry, we identified this protein to be cMyBP-C. These data were confirmed by immunostaining using the p-PKD-Ser744/748 antibody, which displayed a striated pattern similar to the one observed for a regular cMyBP-C antibody. To our knowledge there are no antibodies commercially available for phosphorylated cMyBP-C. Thus, the p-PKD-Ser744/748 antibody can accelerate research into the role of cMyBP-C phosphorylation in cardiomyocytes.
文摘Since its discovery, myosin-binding protein C (cMyBP-C) has become a protein of interest clinically. With emergence of new methodologies and technologies, the structure and functions of cMyBP-C from different aspects can be studied, enabling us to better understand its involvement in certain cardiac conditions. Studying its kinetics of release and clearance from the circulation and by comparing to other conventional biomarkers, it has been reported that cMyBP-C is eligible to be a novel biomarker for several cardiac conditions. Moreover, studying the genetics and their involvement in pathogenic mechanisms has opened the ideas for potential therapeutic strategies. More and more researches are constantly being done to better understand the role of cMyBP-C in dilated cardiomyopathy (DCM). The importance of cMyBP-C to the heart is still actively being investigated. Its presence is however crucial for sarcomere organization and proper regulation of cardiac contraction during systole and complete relaxation during diastole. Genetic mutation in cMyBP-C has been linked to cardiac conditions including hypertrophic and dilated cardiomyopathies. Around 350 types of mutations have already been documented leading to various cardiac conditions and abnormalities. Analyzing human heart samples has enabled us to better understand the importance of cMyBP-C and how its mutations lead to inherited cardiomyopathies. It is therefore necessary to have an update about the research progress of cMyBP-C in relation to DCM and other cardiac conditions.
文摘目的探讨血清心脏肌球蛋白结合蛋白C(c My BP-C)在急性心肌梗死(AMI)患者诊断中的价值。方法选择2014年3月至2015年11月心血管内科收治的AMI患者62例作为病例组,选取正常体检者60例作为对照组。采用双抗体夹心酶联免疫吸附试验(ELISA)法检测血清c My BP-C浓度。比较AMI组与对照组间c My BP-C、肌钙蛋白Ⅰ(c TnⅠ)、肌酸激酶同工酶(CK-MB)和肌红蛋白(Myo)浓度的差异,分析AMI组c My BP-C与c TnⅠ、CKMB和Myo的相关性,同时分析发病时间小于4 h的AMI患者入院时血清c My BP-C和c TnⅠ浓度与对照组的差异,比较急诊经皮冠状动脉介入(PCI)术后12 h与入院时血清c My BP-C和c TnⅠ的差异。结果 AMI组患者血清c My BP-C、c TnⅠ、CK-MB和Myo浓度较对照组均明显升高(P<0.05)。相关性分析显示,AMI组患者c My BP-C浓度与c TnⅠ、CK-MB和Myo浓度均存在正相关(分别为r=0.876、P<0.05;r=0.632、P<0.05和r=0.903、P<0.05)。发病时间小于4 h的AMI患者入院时血清c My BP-C浓度较对照组明显升高(P<0.05),而血清c TnⅠ浓度与对照组比较差异无统计学意义(P>0.05)。行急诊PCI术后12 h血清c My BP-C浓度较入院时明显下降,而c TnⅠ浓度较入院时明显升高(P<0.05)。结论 AMI患者入院时血清c My BP-C、c TnⅠ、CK-MB和Myo浓度较对照组均显著升高且c My BP-C浓度与c TnⅠ、CK-MB和Myo浓度均存在正相关;c My BP-C在发病4 h内即开始升高,提示c My BP-C可以作为诊断AMI的早期生化标志物。AMI患者行急诊PCI术后12 h血清c My BP-C浓度较入院时明显下降,表明c My BP-C可以作为评估PCI术效果的早期指标。
文摘目的探讨心肌肌球蛋白结合蛋白C(c My BP-C)在急性心肌梗死(AMI)中的表达及其临床意义。方法选取2011年1月至2013年12月临朐县人民医院收治的50例AMI患者作为AMI组,其中发病时间<4 h 21例,发病时间≥4 h 29例。另外选择同期健康体检者50例作为健康对照组。统计受试者血清c My BP-C、心脏肌钙蛋白I(c Tn I)、肌红蛋白(Myo)水平,并分析AMI患者血清c My BP-C、c Tn I、Myo与年龄、发病时间、体质指数的相关性。结果 AMI组血清c My BP-C、c Tn I、Myo水平均高于健康对照组[(106±16)μg/L比(18±6)μg/L、(10.76±3.32)μg/L比(0.031±0.003)μg/L、(122±33)μg/L比(23±5)μg/L],差异有统计学意义(P<0.01)。发病时间≥4 h组患者血c My BP-C、Myo、c Tn I水平高于发病时间<4 h组[(109±17)μg/L比(76±9)μg/L,(11.67±3.72)μg/L比(0.042±0.006)μg/L,(130±33)μg/L比(93±16)μg/L,P<0.01]。PCI术后患者血c My BP-C水平低于入院时[(59±11)μg/L比(107±16)μg/L,P<0.01],PCI术后患者血c Tn I、Myo水平高于入院时[(33±6)μg/L比(11±3)μg/L,(136±35)μg/L比(122±33)μg/L,P<0.01];血c My BP-C、c Tn I、Myo与AMI发病时间均呈正相关(P<0.05);血c My BP-C、c Tn I、Myo之间均呈正相关(P<0.05)。结论 c My BP-C可以作为AMI早期诊断的指标之一,还可作为评价PCI术早期效果的指标。
